Porous silicon microcarriers for extended release of metformin: Design, biological evaluation and 3D kinetics modeling

García-Briones, Gabriela S.; Ocampo-Pérez, Raúl; Gómez‐Durán, Cesar F. A.; Neri-Gómez, Teresa

doi:10.1016/j.cej.2019.02.022

Cited by 11 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This provided an optimum pH of 7, with the negatively charged surface of the pSi (Si-O − ) favouring the loading of the positively charged metformin molecules, with electrostatic forces enabling the interaction between the drug molecules and the carriers' surface ( Figure 7). Overall, this study found thermally oxidised pSi to be advantageous as a carrier of metformin, with prolonged release over a period of 26 h [126]. Reproduced with permission from [126].…”

Section: Drug Loading and Release From Psimentioning

confidence: 75%

“…Overall, this study found thermally oxidised pSi to be advantageous as a carrier of metformin, with prolonged release over a period of 26 h [126]. Reproduced with permission from [126].…”

Section: Drug Loading and Release From Psimentioning

confidence: 75%

“…Representative geometry used for modelling the loading kinetics during the adsorption of metformin (MET) onto porous silicon microparticles (µpSip), dimensionless concentration profiles inside the µpSipOx during the adsorption of MET, and in vitro release profiles of pure MET and MET-µpSipOx (oxidised porous silicon microparticles). Reproduced with permission from[126].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon

Jones

Bimbo

2020

Pharmaceutics

View full text Add to dashboard Cite

The poor aqueous solubility of new and existing drug compounds represents a significant challenge in pharmaceutical development, with numerous strategies currently being pursued to address this issue. Amorphous solids lack the repeating array of atoms in the structure and present greater free energy than their crystalline counterparts, which in turn enhances the solubility of the compound. The loading of drug compounds into porous materials has been described as a promising approach for the stabilisation of the amorphous state but is dependent on many factors, including pore size and surface chemistry of the substrate material. This review looks at the applications of mesoporous materials in the confinement of pharmaceutical compounds to increase their dissolution rate or modify their release and the influence of varying pore size to crystallise metastable polymorphs. We focus our attention on mesoporous silicon, due to the ability of its surface to be easily modified, enabling it to be stabilised and functionalised for the loading of various drug compounds. The use of neutron and synchrotron X-ray to examine compounds and the mesoporous materials in which they are confined is also discussed, moving away from the conventional analysis methods.

show abstract

Section: Drug Loading and Release From Psimentioning

confidence: 75%

“…Overall, this study found thermally oxidised pSi to be advantageous as a carrier of metformin, with prolonged release over a period of 26 h [126]. Reproduced with permission from [126].…”

Section: Drug Loading and Release From Psimentioning

confidence: 75%

mentioning

confidence: 99%

See 1 more Smart Citation

Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon

Jones

Bimbo

2020

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Nitrogen adsorption-desorption analysis was performed to figure out the behavior of PI molecule inside the HRI coatings. Specific surface area of the coating was analyzed by Brunauer-Emmett-Teller (BET) method, and pore size distribution was analyzed using Barrett-Joyner-Halenda (BJH) method [19][20][21][22][23][24]. It is found from Figure 2 that contributing pore size for the pore volume is below 10 nm, implying that large pores hardly existed inside the coating.…”

Section: Resultsmentioning

confidence: 99%

Silica-Based Sol-Gel Coating with High Transmission at 1053 and 527 nm and Absorption at 351 nm for Frequency-Converting Crystals in High-Power Laser System

et al. 2019

View full text Add to dashboard Cite

A high-power laser system is employed to drive the fusion ignition to realize sustainable supply of green energy according to the inertial confinement fusion theory, in which frequency-converting crystals are sealed in the terminal vacuum chamber and utilized to turn the incident laser (1053 nm) to the desired one (351 nm). However, the reflected 351 nm laser from the pellet hohlraum that goes back through the frequency-converting crystal is found to be harmful for the upstream elements that are located before the terminal chamber. In this study, a specialized coating system for the frequency-converting crystals was designed and fabricated to both ensure high output power for the fusion and reduce the reflected 351 nm laser energy by absorption. Furthermore, the structural, mechanical, and laser-damage resistant properties of this coating were investigated as well.

show abstract

Porous Silicon Microparticles Enable Sustained Release of GLP‐1R Agonist Peptides for the Treatment of Type 2 Diabetes

Zangabad,

Vasani,

Tong

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

GLP‐1R agonist peptides play a prominent role in the treatment of type 2 diabetes. However, these peptides often suffer from short plasma half‐life, rapid clearance, and low in vivo chemical stability; requiring higher dosages and frequent administration. Although some peptides can be modified to improve these properties, such modification may lead to lower potency and immunogenicity. Here, a subcutaneously (SC) administrable porous silicon microparticle (pSiMP) platform for the sustained release of GLP‐1R agonist peptides is reported. The proof‐of‐concept involves using FDA‐approved exenatide, a potent GLP‐1R agonist, showcasing the platform's efficacy for therapeutic GLP‐1R peptides. pSiMPs with tailored particle size, pore dimensions, and surface chemistry unlock the potential for optimized loading and release of this peptide. The positively charged pSiMPs, with a pore diameter of 8 ± 3 nm, show an impressive loading capacity of 338 ± 42 µg mg−1 (exenatide/pSiMP). This optimized pSiMP formulation demonstrates extended and sustained exenatide release over 2 weeks in a bespoke in vitro SC tissue model. Notably, the pSiMP platform shields the peptide payload from proteolysis. In a mouse model, the SC‐injected formulation exhibits sustained in vivo release of exenatide in plasma for up to 2 weeks.

show abstract

Porous silicon microcarriers for extended release of metformin: Design, biological evaluation and 3D kinetics modeling

Cited by 11 publications

References 56 publications

Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon

Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon

Silica-Based Sol-Gel Coating with High Transmission at 1053 and 527 nm and Absorption at 351 nm for Frequency-Converting Crystals in High-Power Laser System

Porous Silicon Microparticles Enable Sustained Release of GLP‐1R Agonist Peptides for the Treatment of Type 2 Diabetes

Contact Info

Product

Resources

About